Prediction of Histopathologic Response of Primary Breast Cancer by Relative Changes in 18F-FDG Uptake on 18F-FDG PET
| Tumor type or stage | Study | Year | No. of patients | PET timing | PET criterion* | Accuracy† | Response rate‡ |
|---|---|---|---|---|---|---|---|
| LABC | Schelling et al. (38) | 2000 | 22 | After first cycle | 55% | 88% | 7/22 (29%) |
| After second cycle | 55% | 91% | |||||
| Large (>3 cm) and LABC | Smith et al. (39) | 2000 | 30 | After first cycle | 20%§ | 80%¶ (sens, 90%; spec, 74%) | 11/30 (38%) |
| Stages II and III | Rousseau et al. (40) | 2006 | 64 | After first cycle | 40% | 77% | 36/64 (56%) |
| After second cycle | 40% | 87% | |||||
| Large (>3 cm) and LABC | McDermott et al. (41) | 2007 | 96 | After first cycle | 24% | 65%¶ (sens, 100%; spec, 53%) | 13/51 (25%)‖ |
| Midtherapy | 58% | 78%¶ (sens, 100%; spec, 68%) | 14/45 (31%)‖ | ||||
| Large (>3 cm) and LABC | Schwarz-Dose et al. (42) | 2008 | 104 | After first cycle | 45% | 65% | 17/104 (16%) |
| After second cycle | 55% | 64% | |||||
| LABC | Dunnwald et al. (59) | 2008 | 53 | Midtherapy (9 wk after initiation) | 5% increase in tumor blood flow (vs. 5% decrease) | Hazard ratio, 1.7 (P < 0.001) | Overall survival |
↵* Reported as cutoff for relative decrease in SUV, unless otherwise indicated.
↵† Accuracy of 18F-FDG PET for prediction of histopathologic response. sens = sensitivity; spec = specificity.
↵‡ Outcome measure was histopathologic response.
↵§ 18F-FDG uptake was measured as dosage uptake rate instead of SUV.
↵¶ Value was not given in publication; accuracy was calculated on basis of sensitivity, specificity, and response rate.
↵‖ Pathologic response rate among patients who underwent PET at indicated point in therapy; overall response rate was not given.
LABC = locally advanced breast cancer.
All studies summarized in this table were prospectively designed.